Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Rezolute completed enrollment in its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism, with topline data expected mid-December 2026. The single-arm registrational study enrolled 16 participants; interim results showed 7 of the first 8 participants met the primary endpoint, each achieving complete discontinuation of intravenous glucose.
Key figures
- Drug Name
- ersodetug
- Phase Of Trial
- Phase 3
- Enrollment
- 16
- Study name
- upLIFT
- Success threshold
- lower bound of 95% CI for responder rate must be >=30% (response rate >=56%)
- Interim responders
- 7 of 8 first-half participants met primary endpoint
- Topline data timing
- mid-December 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.